Related Experiment Video

Updated: Feb 10, 2026

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
07:31

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs

Published on: May 24, 2016

18.2K

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma

Wenjing Xiao1, Nan Du2, Taoyuan Huang3

  • 1Department of Tumor Radiotherapy, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Shinan District, Qingdao, PR China.

Ebiomedicine
|May 26, 2018
PubMed

Insights

TP53 mutations are linked to worse outcomes in metastatic melanoma patients receiving CTLA-4 blockade immunotherapy. Lower FAS mRNA expression in TP53-mutated tumors may explain this reduced treatment benefit.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • The TP53 gene is involved in cytotoxic T-cell apoptosis.
  • The role of TP53 mutations in predicting immunotherapy response in melanoma is not well understood.

Purpose of the Study:

  • To investigate the association between TP53 mutations and treatment outcomes in metastatic melanoma patients receiving CTLA-4 blockade therapy.
  • To explore potential mechanisms underlying this association using TCGA data.

Main Methods:

  • Analysis of a public cohort (110 patients) with metastatic melanoma treated with CTLA-4 blockade.
  • Utilized The Cancer Genome Atlas (TCGA) data (368 patients) for sequencing, mRNA, and survival analysis.
  • Assessed progression-free survival, overall survival, and response rates in relation to TP53 mutation status.

Main Results:

  • TP53 mutation was significantly associated with poorer progression-free survival (P=0.014) and overall survival (P=0.040).
  • A trend towards poorer response to CTLA-4 blockade was observed in patients with TP53 mutations (P=0.131).
  • These correlations remained significant in multivariate analysis and TP53-mutated tumors showed lower FAS mRNA expression.

Conclusions:

  • TP53 mutation may serve as a negative predictive biomarker for response to CTLA-4 blockade in metastatic melanoma.
  • The findings highlight the importance of TP53 status in guiding immunotherapy decisions for melanoma patients.
Keywords:
Anti-CTLA-4BiomarkerMelanomaTP53Tumor mutational burden

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.9K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

Related Concept Videos

Mutations01:39

Mutations

Overview
94.6K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.6K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.6K